URGN
URGN
NASDAQ · Biotechnology

Urogen Pharma Ltd

$18.17
+0.51 (+2.89%)
As of Mar 25, 2:10 PM ET ·
Financial Highlights (FY 2026)
Revenue
101.58M
Net Income
-142,562,027
Gross Margin
90.2%
Profit Margin
-140.4%
Rev Growth
+23.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 90.2% 90.2% 31.9% 31.9%
Operating Margin -107.1% -96.4% 7.4% 7.0%
Profit Margin -140.4% -133.3% 5.1% 6.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 101.58M 82.27M 574.93M 620.56M
Gross Profit 91.60M 74.20M 183.53M 198.10M
Operating Income -108,747,314 -79,274,730 42.60M 43.31M
Net Income -142,562,027 -103,925,015 29.33M 36.90M
Gross Margin 90.2% 90.2% 31.9% 31.9%
Operating Margin -107.1% -96.4% 7.4% 7.0%
Profit Margin -140.4% -133.3% 5.1% 6.0%
Rev Growth +23.5% +23.5% -7.8% +0.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 316.20M 293.87M
Total Equity 463.52M 437.50M
D/E Ratio 0.68 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -134,944,907 -103,837,406 65.79M 68.95M
Free Cash Flow 30.48M 44.33M